Cargando…

Discovery of a highly potent and orally available importin-β1 inhibitor that overcomes enzalutamide-resistance in advanced prostate cancer

Nuclear transporter importin-β1 is emerging as an attractive target by virtue of its prevalence in many cancers. However, the lack of druggable inhibitors restricts its therapeutic proof of concept. In the present work, we optimized a natural importin-β1 inhibitor DD1 to afford an improved analog DD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Jia-Luo, Yan, Xue-Long, Huang, Dong, Gan, Lu, Gao, Huahua, Fan, Run-Zhu, Li, Shen, Yuan, Fang-Yu, Zhu, Xinying, Tang, Gui-Hua, Chen, Hong-Wu, Wang, Junjian, Yin, Sheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692375/ https://www.ncbi.nlm.nih.gov/pubmed/38045040 http://dx.doi.org/10.1016/j.apsb.2023.07.017

Ejemplares similares

Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer
por: Vander Ark, Alexandra, et al.
Publicado: (2018)

Novel MDM2 Inhibitor XR-2 Exerts Potent Anti-Tumor Efficacy and Overcomes Enzalutamide Resistance in Prostate Cancer
por: Wu, Meng, et al.
Publicado: (2022)

Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase
por: Lin, Hui-Ming, et al.
Publicado: (2021)

SOX8 Knockdown Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer by Inhibiting the Notch Signaling Pathway
por: Du, Zhongbo, et al.
Publicado: (2022)

Discovery of C19-9 as a novel non-RGD inhibitor of αvβ3 to overcome enzalutamide resistance in castration-resistant prostate cancer
por: Pang, Xiaocong, et al.
Publicado: (2023)

Molecular determinants for enzalutamide-induced transcription in prostate cancer
por: Yuan, Fuwen, et al.
Publicado: (2019)

A novel inhibitor of ARfl and ARv7 induces protein degradation to overcome enzalutamide resistance in advanced prostate cancer
por: Li, Yan, et al.
Publicado: (2022)

Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer
por: Culig, Zoran
Publicado: (2017)

Molecular mechanisms of enzalutamide resistance in prostate cancer
por: Blatt, Eliot B., et al.
Publicado: (2019)

Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment
por: Attard, Gerhardt, et al.
Publicado: (2018)

Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model
por: Nguyen, H G, et al.
Publicado: (2014)

A kinome-wide CRISPR screen identifies CK1α as a target to overcome enzalutamide resistance of prostate cancer
por: Liu, Jinghui, et al.
Publicado: (2023)

Inhibition of Rac1 reverses enzalutamide resistance in castration-resistant prostate cancer
por: Chen, Xiaoliang, et al.
Publicado: (2020)

Discovery and Characterization of Potent, Efficacious, Orally Available Antimalarial Plasmepsin X Inhibitors and Preclinical Safety Assessment of UCB7362
por: Lowe, Martin A., et al.
Publicado: (2022)

The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer
por: Wang, Keliang, et al.
Publicado: (2020)

Enzalutamide for patients with metastatic castration-resistant prostate cancer
por: Ramadan, Wijdan H, et al.
Publicado: (2015)

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
por: Rodriguez-Vida, Alejo, et al.
Publicado: (2015)

Hydralazine and Enzalutamide: Synergistic Partners against Prostate Cancer
por: Lopes, Nair, et al.
Publicado: (2021)

Enzalutamide Reduces Oxycodone Exposure in Men with Prostate Cancer
por: Detert Oude Weme, S. E. H., et al.
Publicado: (2023)

A noncanonical AR addiction drives enzalutamide resistance in prostate cancer
por: He, Yundong, et al.
Publicado: (2021)

Targeted suppression of AR-V7 using PIP5K1α inhibitor overcomes enzalutamide resistance in prostate cancer cells
por: Sarwar, Martuza, et al.
Publicado: (2016)

Importins and exportins in cellular differentiation
por: Okada, Norihisa, et al.
Publicado: (2008)

Xenopus importin beta validates human importin beta as a cell cycle negative regulator
por: Delmar, Valerie A, et al.
Publicado: (2008)

Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease
por: Smith, Rebecca, et al.
Publicado: (2020)

Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide
por: El-Amm, Joelle, et al.
Publicado: (2013)

Enzalutamide: A New Agent for the Prostate Cancer Treatment Armamentarium
por: McCutcheon, Stephanie B.
Publicado: (2013)

Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond
por: Linder, Simon, et al.
Publicado: (2018)

Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions
por: Tucci, Marcello, et al.
Publicado: (2018)

A comprehensive characterization of the transcriptome in enzalutamide resistance prostate cancer
por: Wang, Lili, et al.
Publicado: (2021)

Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer
por: Staniszewska, Magdalena, et al.
Publicado: (2021)

Budget Impact of Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer
por: Schultz, Neil M., et al.
Publicado: (2020)

Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment
por: Mei, Zejie, et al.
Publicado: (2022)

Triptolide Inhibits the AR Signaling Pathway to Suppress the Proliferation of Enzalutamide Resistant Prostate Cancer Cells
por: Han, Yangyang, et al.
Publicado: (2017)

Enzalutamide-resistant related lncRNA NONHSAT210528 promotes the proliferation and invasion of prostate cancer
por: Ye, Chen, et al.
Publicado: (2022)

Discovery of a Novel Series of Potent, Selective, Orally Available, and Brain-Penetrable C1s Inhibitors for Modulation of the Complement Pathway
por: Ikeda, Zenichi, et al.
Publicado: (2023)

A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone
por: Graff, Julie N, et al.
Publicado: (2020)

hsa_circ_0001275 Is One of a Number of circRNAs Dysregulated in Enzalutamide Resistant Prostate Cancer and Confers Enzalutamide Resistance In Vitro
por: Lim, Marvin C. J., et al.
Publicado: (2021)

Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses
por: Li, Qiuhui, et al.
Publicado: (2018)

The molecular basis for the regulation of the CBC by the importins
por: Dias, Sandra M.G., et al.
Publicado: (2009)

Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer
por: Golshayan, Ali R, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_sef7fabhjlbaq4019fri6vk43k